Steven Gill, the British neurosurgeon who ran that first GDNF infusion trial, believes the cause of the toxicity was the improper infusion of the drug into the monkeys' brains.
Prior to the FDA action, patients were required to get an infusion of rituximab the first day, followed by a pre-treatment diagnostic dose of radiolabeled indium-111 Zevalin.
Citigroup, Goldman Sachs, Wells Fargo, JPMorgan Chase, Bank of America, Merrill Lynch and Morgan Stanley are among the institutions that will be first in line for the government infusion.